New guidance to improve sample size calculations for trials

Eliciting the target difference Suzie Cro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect. Main text: This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA2 that aim to provide evidence-based guidance on systematically determining the target effect size, or difference and the resultant sample sizes for trials. In addition to surveying methods that researchers are using in practice, the research team met with various experts (statisticians, methodologists, clinicians and funders); reviewed guidelines from funding agencies; and reviewed recent methodological literature. The DELTA2 guidance stresses specifying important and realistic differences, and undertaking sensitivity analyses in calculating sample sizes. It gives recommendations on how to find appropriate differences, conduct the sample size calculation(s) and how to report these in grant applications, protocols and manuscripts. It is hoped that this will contribute not only to better powered studies, but better reporting and reproducibility and thinking about what a trial should be designed to achieve. Conclusions: The DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.

Original languageEnglish (US)
Article number605
JournalTrials
Volume19
Issue number1
DOIs
StatePublished - Nov 5 2018

Fingerprint

Sample Size
Research Personnel
Manuscripts
Organized Financing
Research
Research Design
Odds Ratio
Guidelines
Health

Keywords

  • Effect size
  • Power
  • Randomized controlled trials
  • Sample size
  • Target difference

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

New guidance to improve sample size calculations for trials : Eliciting the target difference Suzie Cro. / Bell, Melanie L.

In: Trials, Vol. 19, No. 1, 605, 05.11.2018.

Research output: Contribution to journalArticle

@article{ffd6227fcfc24a4abaa484575c57bfc0,
title = "New guidance to improve sample size calculations for trials: Eliciting the target difference Suzie Cro",
abstract = "Background: Sample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect. Main text: This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA2 that aim to provide evidence-based guidance on systematically determining the target effect size, or difference and the resultant sample sizes for trials. In addition to surveying methods that researchers are using in practice, the research team met with various experts (statisticians, methodologists, clinicians and funders); reviewed guidelines from funding agencies; and reviewed recent methodological literature. The DELTA2 guidance stresses specifying important and realistic differences, and undertaking sensitivity analyses in calculating sample sizes. It gives recommendations on how to find appropriate differences, conduct the sample size calculation(s) and how to report these in grant applications, protocols and manuscripts. It is hoped that this will contribute not only to better powered studies, but better reporting and reproducibility and thinking about what a trial should be designed to achieve. Conclusions: The DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.",
keywords = "Effect size, Power, Randomized controlled trials, Sample size, Target difference",
author = "Bell, {Melanie L}",
year = "2018",
month = "11",
day = "5",
doi = "10.1186/s13063-018-2894-y",
language = "English (US)",
volume = "19",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - New guidance to improve sample size calculations for trials

T2 - Eliciting the target difference Suzie Cro

AU - Bell, Melanie L

PY - 2018/11/5

Y1 - 2018/11/5

N2 - Background: Sample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect. Main text: This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA2 that aim to provide evidence-based guidance on systematically determining the target effect size, or difference and the resultant sample sizes for trials. In addition to surveying methods that researchers are using in practice, the research team met with various experts (statisticians, methodologists, clinicians and funders); reviewed guidelines from funding agencies; and reviewed recent methodological literature. The DELTA2 guidance stresses specifying important and realistic differences, and undertaking sensitivity analyses in calculating sample sizes. It gives recommendations on how to find appropriate differences, conduct the sample size calculation(s) and how to report these in grant applications, protocols and manuscripts. It is hoped that this will contribute not only to better powered studies, but better reporting and reproducibility and thinking about what a trial should be designed to achieve. Conclusions: The DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.

AB - Background: Sample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect. Main text: This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA2 that aim to provide evidence-based guidance on systematically determining the target effect size, or difference and the resultant sample sizes for trials. In addition to surveying methods that researchers are using in practice, the research team met with various experts (statisticians, methodologists, clinicians and funders); reviewed guidelines from funding agencies; and reviewed recent methodological literature. The DELTA2 guidance stresses specifying important and realistic differences, and undertaking sensitivity analyses in calculating sample sizes. It gives recommendations on how to find appropriate differences, conduct the sample size calculation(s) and how to report these in grant applications, protocols and manuscripts. It is hoped that this will contribute not only to better powered studies, but better reporting and reproducibility and thinking about what a trial should be designed to achieve. Conclusions: The DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.

KW - Effect size

KW - Power

KW - Randomized controlled trials

KW - Sample size

KW - Target difference

UR - http://www.scopus.com/inward/record.url?scp=85056095660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056095660&partnerID=8YFLogxK

U2 - 10.1186/s13063-018-2894-y

DO - 10.1186/s13063-018-2894-y

M3 - Article

VL - 19

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 605

ER -